The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...
"We look forward to releasing topline data results from our Phase 2 BMT-801 clinical study of our melanocortin-4 receptor ...
As Ozempic and other GLP-1 drugs explode in popularity, driven by their off-label use for rapid weight loss and viral social media trends, the pharmaceutical industry faces unprecedented challenges.
The company says the treatment can help in “providing an off-ramp from GLP-1 therapies” in terms of weight maintenance, with ...
Achieves Robust Financial Performance with 74% Gross Margin and Strategic Public Offering, Bolstering Resources for Continued Growth and Innovation.Elevai Enfinity Clinical Trials Showcase Breakthroug ...
Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health ...
A mum says she almost died when she accidentally injected 'five times' the recommended dose of a jab she was told would help ...
2-Year U.S. Treasury Note Continuous Contract $102.664-0.035-0.03% 5-Year U.S. Treasury Note Continuous Contract $106.484-0.086-0.08% 10-Year U.S. Treasury Note Continuous Contract $109.313-0.109 ...